APC Anti-BOB1 antibody [SP92],Abcam,AB320616
Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies . How are conjugated primary antibodies validated? This conjugated primary antibody is released using a quantitative quality control method that evaluates binding affinity post-conjugation and efficiency of antibody labeling. For suitable applications and species reactivity, please refer to the unconjugated version of this clone.
Host
Rabbit
Reactivity
Human
Application
Antibody Labelling, Target Binding Affinity, IHC-P
Conjugate
APC
Platform ID
BAB892639587
Abcam
Contact
Tel: +44 (0)1223 696000
Fax: +44 (0)1223 215 215
Email:
Specifications
Scientific Background
Target data Transcriptional coactivator that specifically associates with either POU2F1/OCT1 or POU2F2/OCT2 (PubMed : 7859290). It boosts the POU2F1/OCT1 mediated promoter activity and to a lesser extent, that of POU2F2/OCT2 (PubMed : 7779176). It recognizes the POU domains of POU2F1/OCT1 and POU2F2/OCT2 (PubMed : 7779176). It is essential for the response of B-cells to antigens and required for the formation of germinal centers (PubMed : 7623806, PubMed : 7859290). Regulates IL6 expression in B cells as POU2F2/OCT2 coactivator (By similarity). See full target information POU2AF1
Category Paths
- Products>Primary Antibodies>Monoclonal Antibodies
- Products>Primary Antibodies>IHC Antibodies
- Products>Primary Antibodies>Recombinant Antibodies
Please provide the required information below so that we can quickly source your products.